Treatment by Disease Severity
Mild to Moderate — Outpatient Treatment
Most COVID-19 cases are mild or moderate and can be managed at home. High-risk patients with mild-to-moderate illness may be candidates for antiviral therapy.
Paxlovid (Nirmatrelvir / Ritonavir)
Status: FDA-approved for adults with mild-to-moderate COVID-19 at high risk for severe disease. Adolescents aged 12–17 (≥40 kg) are covered separately under an Emergency Use Authorization (EUA), not the full approval.
How it works: Nirmatrelvir inhibits the SARS-CoV-2 main protease (Mpro), blocking viral replication. Ritonavir boosts nirmatrelvir levels by inhibiting its metabolism.
Efficacy: Original EPIC-HR trial: ~89% reduction in hospitalization/death vs. placebo in unvaccinated high-risk adults. Real-world effectiveness in the vaccinated population is lower but still significant, particularly for older adults and the immunocompromised.
Window: Must start within 5 days of symptom onset.
Key concern: Due to significant CYP3A4 drug interactions, prescribers review all current medications before initiating Paxlovid — it is contraindicated or requires dose adjustment with statins, certain anticoagulants, immunosuppressants, and others.
Paxlovid rebound: A subset of patients (estimated 5–10%) experience symptom return 2–8 days after completing the 5-day course. Rebound is generally mild. No evidence that a second Paxlovid course improves outcomes. Research also suggests Paxlovid may reduce the risk of Long COVID, making early treatment a priority for eligible high-risk patients.
Remdesivir (Veklury) — Outpatient
Status: FDA-approved for adults and pediatric patients — including neonates weighing at least 1.5 kg — with mild-to-moderate COVID-19 at high risk for severe disease who are not hospitalized. The outpatient course is started within 7 days of symptom onset.
How it works: Nucleotide prodrug that inhibits SARS-CoV-2 RNA-dependent RNA polymerase, blocking viral replication.
Efficacy: PINETREE trial: 3-day intravenous (IV) course reduced hospitalization/death by 87% vs. placebo in high-risk, unvaccinated adults.
Limitation: Requires IV infusion — administered in an outpatient infusion center, not at home. May be preferred when Paxlovid drug interactions are prohibitive.
Molnupiravir (Lagevrio)
Status: Not FDA-approved — available only under an Emergency Use Authorization (EUA) for adults with mild-to-moderate COVID-19 at high risk for severe disease, and only when other authorized treatments are inaccessible or clinically inappropriate.
How it works: Ribonucleoside analog that introduces errors into the viral RNA, leading to "error catastrophe."
Efficacy: MOVe-OUT trial: ~30% reduction in hospitalization/death — significantly less effective than Paxlovid. Not recommended as first-line therapy.
Concern: Theoretical mutagenic risk has limited its use. Not recommended during pregnancy.
Severe — Hospitalized Patients
Dexamethasone
Recommended for: Hospitalized patients requiring supplemental oxygen or mechanical ventilation.
Efficacy: RECOVERY trial (6,425 patients): 36% reduction in 28-day mortality in ventilated patients; 18% in those requiring oxygen without ventilation. No benefit — and possible harm — in patients not requiring oxygen.
Why it works: In severe COVID-19, the immune system's over-response (cytokine storm) causes much of the lung damage. Dexamethasone suppresses this excessive inflammation.
Mechanism contrast: Antivirals target the virus directly; dexamethasone targets the dysregulated immune response that causes severe disease.
Remdesivir (Veklury) — Inpatient
Recommended for: Hospitalized adults and children with COVID-19 requiring supplemental oxygen (but not high-flow oxygen or ventilation).
Efficacy: ACTT-1 trial: Reduced median time to recovery from 15 to 10 days in patients requiring oxygen. Mortality benefit was less clear in subsequent trials.
Dosing: 5-day IV course (200 mg loading dose, then 100 mg daily).
Baricitinib (Olumiant)
Recommended for: Hospitalized adults with severe or critical COVID-19 requiring supplemental oxygen.
How it works: JAK1/JAK2 inhibitor that reduces the inflammatory signaling cascade driving cytokine storm. Often used in combination with dexamethasone.
Efficacy: COV-BARRIER trial: Significant reduction in 28-day all-cause mortality when combined with standard of care including dexamethasone.
Home Care for Mild COVID-19
For most vaccinated, otherwise-healthy adults with mild COVID-19, supportive care at home is the primary approach:
- Rest — your immune system does the work; physical exertion during acute illness slows recovery
- Hydration — fever and respiratory illness increase fluid losses; staying well hydrated supports recovery
- Fever & pain relief — the CDC notes that acetaminophen (Tylenol) or ibuprofen are both appropriate options; follow package dosing instructions
- Monitor oxygen levels — a pulse oximeter can detect silent hypoxia; readings below 92% warrant medical attention
- Isolate — protect household members, especially high-risk individuals
- High-risk individuals — the CDC identifies adults over 65, immunocompromised individuals, and those with significant underlying conditions as high-priority candidates for antiviral treatment; these individuals should contact a healthcare provider promptly after a positive test to discuss eligibility
Sources & References
- CDC. Clinical Care of COVID-19 (treatment). cdc.gov
- U.S. Food and Drug Administration. FDA Approves First Oral Antiviral for Treatment of COVID-19 in Adults (Paxlovid). May 25, 2023. fda.gov
- U.S. Food and Drug Administration. Lagevrio (molnupiravir) — Letter of Authorization (EUA). fda.gov
- World Health Organization. Therapeutics and COVID-19: living guideline. who.int
